LINK Drs. Eric Hoffman and Kanneboyina Nagaraju could have chosen a number of cities to relocate their growing business when they began to outgrow their lab space in Washington, D.C. With its established lab spaces, educated young talent, and business acceleration programs, Halifax was the clear winner. ReveraGen BioPharma was operating out of the Children’s National Medical Center in Washington, DC, where Dr. Hoffman and his team were developing a new drug, Vamorolone, for Muscular Dystrophy. However, with traditional approaches to drug development taking upwards of 15 years and a billion dollars to produce they faced many barriers. The industry was also experiencing changes at the time, that caused Dr. Hoffman to re-evaluate the research models. “Common diseases are becoming stratified into smaller and smaller groups and each group requires its own treatment regimen. There has been a lot of emphasis on rare diseases and orphan drug development over the last number of years,” says Dr. Hoffman. In recent years, there has been an increase in the number of incentive programs available for rare diseases research and with the Internet’s ability to consolidate those stakeholder communities internationally, it has created new opportunities for researchers. But, this also creates a fundamental problem; because these drugs are very targeted and if each drug costs a billion dollars and 15 years to make, the costs to patients will be astronomical. Realizing the shift in the industry and the need for better services, Drs. Hoffman and Nagaraju opened AGADA Biosciences in the Life Sciences Research Institute in 2013. The company’s primary goal is to meet the rapidly growing need for services that accelerate drug development for orphan diseases, with specific expertise in preclinical efficacy studies with biomarkers support. ReveraGen BioPharma recently developed a drug for Muscular Dystrophy that AGADA was able to bring to phase II clinical trials with Muscular Dystrophy patients. “At this point in time, it looks like we will receive approval in about eight years and for 30 million as opposed to 15 years and a billion dollars,” says Dr. Hoffman. AGADA’s success can be attributed to their first step of de-risking drugs and avoiding late stage failures. To do this, AGADA uses Dalhousie University’s state of the art mouse lab facility, also located in the Life Sciences Research Institute. Mice who develop muscular dystrophy have the same genetic mutation as human patients do, so if you develop a drug that makes the mice better, then you have de-risked that drug considerably. Dr. Hoffman states that proof of principle in an animal model is becoming increasingly requested by regulators, particularly in orphan diseases. “Traditionally, animal testing was used for toxicity, making sure you weren’t making an animal terribly sick before making a human terribly ill,” says Dr. Hoffman. “But, the whole paradigm is shifting – at AGADA we are working to make the mice better which anticipates making the human better.” AGADA has become the top tester of drugs in muscular dystrophy models and has grown quickly over the past three years. The company has seen a 60 percent growth rate each year and currently employs 13 people, with more than half coming from Nova Scotia universities. “One of the reasons we chose Halifax was because of the quality of a young, educated workforce,” says Dr. Hoffman. “We participate in the co-op programs at Dalhousie and Acadia because we see the value in keeping talent in the province.” Most recently, AGADA invested one million dollars along with three million from ACOA and half of a million from Dalhousie to develop “A Scientific and Clinical Hub for Orphan Drug Development” in Halifax that will help to accelerate orphan drug development beginning with developing treatments for three indications. The diseases in question are labeled “orphan diseases” but they occur in one in 5,000 to one in 10,000 babies. Preclinical research with the new therapies in zebrafish and mice have shown promising results that are expected to propel these programs through the clinical research stage. The project is expected to put Halifax and Nova Scotia on the map as the best place in Canada and one of the best sites in the world for such research and clinical work. Learn more about AGADA Biosciences at agadabio.com]]>
BIONOVA CONTACT
#46 1344 Summer Street
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]
Halifax, Nova Scotia
Canada B3H 0A8
Phone: 902-421-5705
Fax: 902-421-2733
Email: [email protected]
Recent Posts
- NEWS RELEASE: Doris Grant appointed Vice President Business Development and Strategy at BioNova
- MARS VR Lab
- Workinsights
- NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021
- NEWS RELEASE: BioNova’s BioPort 2021 Conference for Health and Life Sciences Kicks-Off Today
Business Wire National BioTech News
- DIC Algae Oil Sulfurized Extreme Pressure Additives Present Promising Alternatives to Lard Oils and Vegetable Oils in Lubricating Oils, Metalworking Fluids, and Greases
- Cybin to Participate at the 27th Annual Milken Institute Global Conference
- MindMed to Present at Upcoming May Medical Conferences
- BrightFocus Foundation Announces $10M in New Funding Across Brain and Vision Research, Celebrates Historic Diversity of Grant Award Recipients
- Antibe Announces Appointment of Receiver
- Binarly Launches Next-Generation Transparency Platform to Elevate Software Supply Chain Security
- Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO
- ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management
- Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
- Checkerspot Announces Patent for Non-Genetically Engineered High-Oleic Microalgae Oil
RECENT NEWS
- NEWS RELEASE: Doris Grant appointed Vice President Business Development and Strategy at BioNova February 9, 2023
- MARS VR Lab January 25, 2022
- Workinsights January 25, 2022
- NEWS RELEASE: BioNova Announces MycoFutures North Atlantic as the Winner of the Eleventh Annual BioInnovation Challenge (BIC) at BioPort 2021 November 8, 2021
- NEWS RELEASE: BioNova’s BioPort 2021 Conference for Health and Life Sciences Kicks-Off Today November 2, 2021
- NEWS RELEASE: BioNova Selects Eight Semi-Finalists to Participate in the 11th Annual BioInnovation Challenge August 24, 2021
RECENT TWEETS
Notice: Trying to get property 'full_text' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 206
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1033
Notice: Trying to get property 'id_str' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1033
Notice: Trying to get property 'favorite_count' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1064
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1104
Notice: Trying to get property 'name' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1104
·
@
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1123
Notice: Trying to get property 'screen_name' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1123
Notice: Trying to get property 'id' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1123
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1307
Notice: Trying to get property 'screen_name' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1307
Notice: Trying to get property 'id' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 1307
Notice: Trying to get property 'id' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 601
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 601
Notice: Trying to get property 'screen_name' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 601
Notice: Trying to get property 'id' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 619
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 619
Notice: Trying to get property 'screen_name' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 619
Notice: Trying to get property 'user' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 579
Notice: Trying to get property 'screen_name' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 579
Notice: Trying to get property 'id' of non-object in /home/bionova/public_html/wp-content/plugins/feed-them-social/feeds/twitter/class-fts-twitter-feed.php on line 579